An optimistic approach to nanotechnology in Alzheimer's disease management: An overview
Document Type
Article
Publication Date
9-1-2023
Abstract
Alzheimer's disease (AD) imparts a neurodegenerative impact on mental ability, dementia, and behavioral alterations that have been observed in the ten to twenty years before the manifestation of symptoms. The major problem lies in early diagnosis as well as management due to unavailability of authenticated biomarkers. Recent progress in nanotechnology possesses the potential to offer inexpensive screening and therapeutic solutions on a mass scale. Targeted drug delivery through nanoparticles (NPs) may efficiently cross the blood-brain barrier (BBB) with minimal adverse reactions. In addition, NPs with improved magnetic and ocular characteristics may be employed in early diagnosis. With an explicit reference to the efficacy of NP-based medicine delivery in the specific environment of the central nervous system (CNS), this technology results in early diagnosis and treatment. This review provides comprehensive information on AD and its management with special emphasis on nanotechnology advancements, nanomaterials (NMs) employed along with nanomedicines, lipid-based nanoparticles, antibody-coated nanoparticles, nanoparticle therapy, therapeutic strategies, and promising protein targets for new drug research on AD.
Keywords
Alzheimer's disease, Nanoparticles, Drug carriers, Biocompatible, Amyloid targets, Biomarkers
Divisions
nanocat
Funders
None
Publication Title
Journal of Drug Delivery Science and Technology
Volume
86
Publisher
Elsevier
Publisher Location
RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS